The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

How can pharma align its brand strategy with the NHS Reset?

Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era There is a...

Covid-19 redefines rules of customer engagement

Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs Covid-19 has...

Covid-19: how is it impacting on the NHS Long-term Plan?

Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in...

Covid-19: what could it mean for the diabetic population?

Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it On March 28,...

Mapping the intricate oncology landscape

Simon Grime, of Wilmington Healthcare, explains how data and intelligence tools help pharma deliver tailored engagement programmes to diverse...

GIRFT: Can ophthalmology point to where other NHS areas are heading?

Oli Hudson, Content Director at Wilmington Healthcare, looks at the latest GIRFT report and sees what lessons it holds for the MedTech industry at...

What next for biosimilars?

James Roach, Director at West Essex ICP, looks at the future for biosimilar medicines, surveys a future landscape where medicines management will be...

The Value Exchange

Simon Grime, of Wilmington Healthcare, explains the principles of exchanging value with customers to gain trust and consent Today in B2B...

A Tory win: What now for MedTech?

Oli Hudson, of Wilmington Healthcare, explores some of the issues affecting MedTech in 2020 now the Conservatives have won power For healthcare...

[Download] Innovations in Oncology supplement

We’re supporting the Innovations In Oncology campaign with Media Planet Launched initially throughout the Guardian, Innovations in Oncology...

[Article] A late stage killer: why early diagnosis is so important

The NHS’ Long Term Plan places cancer at the heart of its agenda Local systems have been given ambitious targets to improve screening, diagnosis...

Mapping NHS change is key to customer engagement

Simon Grime, of Wilmington Healthcare, explains how data and intelligence can help industry understand and engage customers in the new integrated...

Early diagnosis underpins NHS cancer strategy

Faster cancer diagnosis is a key ambition of the NHS Long-term Plan, which says that the proportion of cancers diagnosed at stages one and two should...

[Article] Why diagnostics is the next big challenge for NHS cancer services

The coming decade will see a new wave of advanced biotech capable of assisting enormous strides forward in cancer care, with potential for safer,...